The Patient with Newly Diagnosed Ulcerative Colitis

KEY POINTS / CLINICAL PEARLS

Patients can be relatively ill informed regarding the nature of their UC, its management, and its ultimate prognosis.
Generally, disease extent is divided into three categories: ulcerative proctitis, left-sided disease, and pancolitis.
A simple approach with frequently asked questions (FAQs) is a highly desirable and efficient means of transmitting information.
Clinical experience reinforces that most patients have similar questions upon diagnosis with UC.
Anticipating these questions and tailoring them to a particular patient's disease severity and extent should streamline follow-up and also mitigate confusion.

References

  1. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559–68.
  2. Satsangi J, Siverberg MS, Vermeire S, Colombel J-F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.
  3. Yamamoto T, Nakahigashi M, Saniabadi AR. Diet and inflammatory bowel disease – epidemiology and treatment. Aliment Pharmacol Ther 2009;30:99–112.
  4. Rosenberg LN, Peppercorn MA. Efficacy and safety for drugs for ulcerative colitis. Expert Opin Drug Saf 2010;9:573–92.
  5. Ǿrding Olsen K, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease and after surgery compared with a population sample. Gastroenterology 2002;122:15–9.
  6. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501–23.
  7. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138:738–45.